Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases

Title
Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
Authors
Keywords
-
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 87, Issue 6, Pages 871-877
Publisher
Springer Science and Business Media LLC
Online
2021-04-01
DOI
10.1007/s00280-021-04262-w

Ask authors/readers for more resources

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started